Iron Bioavailability From Encapsulated Ferrous Sulphate
Iron Bioavailability From Salt Fortified With Ferrous Sulphate, Zinc Sulphate and Ascorbic Acid Encapsulated in a Polymer Jacket
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Dietary supplement: non-encapsulated FeSO4
- Dietary supplement: encapsulated FeSO4, before cooking
- Dietary supplement: encapsulated FeSO4, after cooking
- Dietary supplement: non-encapsulated FeSO4 + ascorbic acid
- Dietary supplement: encapsulated FeSO4 + ascorbic acid, before cooking
- Dietary supplement: encapsulated FeSO4 + ascorbic acid, after cooking
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8092
- Human Nutrition Laboratory, ETH Zurich
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female, 18 to 40 years old
- Marginal iron status (ferritin < 25 ng/ml)
- Body weight < 65 kg
- Normal body Mass Index (18.5 - 25 kg/m2)
- Signed informed consent
Exclusion Criteria:
- Pregnancy (assessed by a pregnancy test) / intention to become pregnant
- Lactating up to 6 weeks before study initiation
- Moderate or severe anaemia (hemoglobin < 9.0 g/dL)
- Elevated C-reactive protein (> 5.0 mg/L)
- Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
- Continuous/long-term use of medication during the whole study (except for contraceptives)
- Consumption of mineral and vitamin supplements within 2 weeks prior to 1st meal administration
- Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
- Earlier participation in a study using Fe stable isotopes or participation in any clinical study within the last 30 days
- Participant who cannot be expected to comply with study protocol (e.g. not available on certain study appointments or difficulties with blood sampling)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: non-encapsulated FeSO4
Maize porridge with salt fortified with non-encapsulated FeSO4
|
|
|
Experimental: encapsulated FeSO4, before cooking
Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
|
|
|
Experimental: encapsulated FeSO4, after cooking
Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
|
|
|
Experimental: non-encapsulated FeSO4 + ascorbic acid
Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
|
|
|
Experimental: encapsulated FeSO4 + ascorbic acid, before cooking
Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
|
|
|
Experimental: encapsulated FeSO4 + ascorbic acid, after cooking
Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in the isotopic ratio of iron in blood at week 2
Time Frame: baseline, 2 weeks
|
The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes.
|
baseline, 2 weeks
|
|
Change from week 2 in the isotopic ratio of iron in blood at week 4
Time Frame: 2 weeks, 4 weeks
|
The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes.
|
2 weeks, 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Anemia, Hypochromic
- Anemia
- Iron Metabolism Disorders
- Anemia, Iron-Deficiency
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Ascorbic Acid
- Fesoterodine
Other Study ID Numbers
Other Study ID Numbers
- Omnisalt
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.